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Objectives: Estimation of health gains associated to early diagnosis and treat-
ment of Chronic Obstructive Pulmonary Disease (COPD) in Portugal over a 20 year 
horizon. MethOds: A stochastic individually based dynamic microsimulation 
model was built generating the evolution of diagnosed and undiagnosed COPD 
prevalences and severity distribution over four stages. Exacerbation frequencies 
and quality of life were associated to severity stages. Smoking habits were taken 
into account since smoking is the main risk-factor of COPD and smoking cessa-
tion is the most effective strategy to slowdown disease progression. The model 
defines annual probabilities for individuals to develop COPD according to sex, 
age and smoking habits. Individuals with COPD progress depending on disease 
stage and smoking behavior. Intervention health benefits were estimated as the 
difference between the status quo and an intervention scenario. In the interven-
tion scenario, smokers and ex-smokers aged 40 and over are screened in primary 
healthcare settings and selectively referred to smoking cessation programs. When 
diagnosed with COPD, patients progress more slowly and have higher quality of 
life due to medication and to less frequent exacerbation episodes. Health benefits 
of the intervention were estimated as the population life-years (LY) and quality-
adjusted life-years (QALYs) difference between the scenarios. Results: Over the 
20 years more than 2.8 million individuals are screened. With discounting at 5%, 
the intervention resulted in gains of 33,230 LY for men and 16,990 LY for women 
while incremental QALYs were 91,586 and 25,983 respectively. Serious exacerba-
tion events are 2.4% lower in the intervention scenario. cOnclusiOns: These 
results show that early diagnosis and early treatment could lead to substantial 
health gains for the Portuguese population in a 20 year time horizon.
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Objectives: The Medical Technologies Evaluation Programme (MTEP) was set up 
by NICE in 2009 to identify new medical devices and diagnostics that could improve 
patient experience and outcomes whilst driving healthcare efficiencies. The pur-
pose of this study was to examine whether procurement managers and key stake-
holders reviewing medical technologies in England and markets beyond are aware 
of NICE’s MTEP and whether they would use the review when considering uptake 
and use of a novel technology. MethOds: A systematic review was undertaken 
for published literature on MTEP. Both an online survey and telephone interviews 
were used with procurement managers and key stakeholders to elicit further 
insight into the relevance of an MTEP review and its impact beyond England. 
Findings were collated and analysed thematically. Results: Procurement manag-
ers and key stakeholders reviewing medical technologies in England were aware 
of MTEP and used the outcomes from MTEP to assist in their decision making 
criteria. However, there are only a limited number of technologies that have gone 
through the programme and therefore its usefulness as a general resource is 
limited. Other markets often look for HTA having been performed on medical 
technologies and will broadly utilise data from MTEP where nothing has been 
performed in their local markets. Inconsistencies in healthcare costs are a major 
factor for not reviewing HTA from different markets. cOnclusiOns: Procurement 
managers and key stakeholders reviewing medical technologies in England will 
use HTA, specifically NICE’s MTEP, if this data is available for the product they are 
reviewing. Stakeholders in markets outside of England will use this data as part of 
their assessment for uptake, but will look to local guidelines as a first step. NICE’s 
MTEP is viewed as a robust method for assessment of a technology; however, cost 
data is largely only applicable in England.
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Objectives: Lung cancer is the most common cause of death from cancer world-
wide. Yet, screening for lung cancer remains controversial. We compared the risks 
and benefits of lung cancer screening with low-dose helical CT (LDCT) relative 
to chest x-ray (CXR). Concerns have been raised about recommending LDCT as 
a routine screening tool because of the potential harms, including cumulative 
radiation risks. MethOds: We developed a decision analytic model to compare 
LDCT and CXR under alternative screening scenarios, and estimate the number of 
radiation-induced cancers due to LDCT and CXR exposure. The age and sex specific 
model was calibrated for Canada, using National Lung Screening Trial (NLST) and 
Prostate, Lung, Colorectal and Ovarian trial (PLCO) data. Three alternative strate-
gies were compared: regular screening with LDCT, screening with CXR, and no 
screening. Results: We compared radiation risks to estimated cancers prevented, 
using age and gender- specific projections. The average effective radiation dose for 
LDCT is only 22% (1.4 mSv) of the standard chest CT (7 mSv). However, the effective 
dose might be 20% to 23% higher for females than males. The average effective 
dose for CXR ranges 0.01 mSv - 0.06 mSv. LDCT showed a 20% reduction in lung 
cancer mortality compared to CXR. This translated into 3 fewer deaths from lung 
cancer per 1000 high-risk individuals screened with LDCT. However, more than 
90% of positive screened results were false positive findings. Over 97% of new 
lung cancer cases are in high-risk adults aged 50 years and older. cOnclusiOns: 
Concerns have been raised about recommending LDCT as a routine screening tool 
for lung cancer. Our model addresses a number of public policy questions regard-
ing who should be targeted for screening and what the trade-offs are in terms of 
potential harms and benefits.
from paid databases of Slovak authority National Center for Health Information that 
collects the outputs of provided health care. The data were focused on totally or 
partly reimbursed medical devices from public health insurance funds. The selected 
group was medical devices for people with diabetes. The most recent data were 
from 1.1. 2009 - 31.12. 2013. It was used basic and advanced statistic processing by 
Microsoft Excel. Results: Referring to the Center for Health Information, in the 
observed period, the share of MDO on total consumption of MD stagnated (MDO/
MD2009= 4.71%; MDO/MD2013= 4.50%; Δ MDO/MD2009-2013= -0.21%). The total quan-
titative consumption MDO increased (Δ 2009-2013= 874 313pcs/22.22%; max2012= 4 
809 613pcs; min2009= 3 935 300pcs; AVG= 4 372 153pcs; Mean= 4 429 095pcs; 
SD= 346 405).The share of MDO on total reimbursementof MD stagnated (MDO/
MD2009= 8.31%; MDO/MD2013= 8.01%; Δ MDO/MD2009-2013= -0.30%). The total 
reimbursement in the observed period increased (Δ 2009-2013= 1 889 707€ /17.73%; 
max2013= 12 545 398€ ; min2010= 10 383 600€ ; AVG= 11 308 972€ ; Mean= 11 433 
975€ ; SD= 847 739). The share of MDO on the patient supplements of MD stagnated 
(MDO/MD2009= 0.44%; MDO/MD2013= 0.01%; Δ MDO/MD2009-2013= -0.43%). The total 
patient supplements decreased (Δ 2009-2013= -13 335 € /-97.03%; max2009= 13 743€ ; 
min2013= 408€ ; AVG= 4 571€ ; Mean= 1 243€ ; SD= 5 786). cOnclusiOns: The ostomy 
medical devices and properly caring for ostomy can maintain a high quality of life 
for patients. Convenient reimbursement policy and almost none supplements for 
patients facilitates patient care of their own health.
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Objectives: With a proportion of 57 to 80% leg ulcers are the most frequent 
chronic wounds next to decubitus and diabetic foot ulcers. Because of the high 
disease burden and the economic relevance, qualified and timely therapy is highly 
important. One of the constant aspects of causal therapy of venous leg ulcers is 
the medical compression therapy. Due to regional disparities in the treatment of 
venous leg ulcers, the question of economic effects arises. MethOds: A discrete 
event simulation model for conducting health economic evaluations in patients 
with chronic wounds from the perspective of German statutory health insurances 
has been developed. It contains different treatment and financing options. The 
effectiveness of compression therapy has been observed with available data from 
clinical studies. Cost data were implemented from a cross-sectional study. The pro-
portion of patients with compression therapy is based on recent data of the Barmer 
GEK. Results: The average costs for compression therapy are 230 € per patient and 
year. A pilot run of the model analyses indicates significant differences in costs 
between the regions, depending on the utilisation of compression therapy. The 
highest total costs of chronic wound treatment were generated in the federal states 
with the lowest prescription rates of compression therapy and the lowest costs in 
those states with the highest utilisation of compression treatment. cOnclusiOns: 
An increased proportion of patients with compression therapy is associated with 
an increase in the healing rate and interrelated cost savings for the German health 
care system.
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Objectives: Upcoming changes in German healthcare regulation strengthen 
the need for real world evidence (RWE) analyses during market access of medical 
devices. RWE offers various opportunities to address different needs of diverse 
stakeholders of medical devices. Aim of this analysis was to identify the current 
status of RWE studies in the field of medical devices in Germany. MethOds: A 
PubMed based literature review was performed. All publications in German/English 
language describing the use of medical devices in a real world setting in Germany 
were included. Publications were stratified by study design, type of RWE data and 
type of research question. Data categories were claims data, registry data and other 
data sources. Research questions were distinguished between brand-specific and 
non-brand-specific assessments. Results: In total, 39 publications were included 
in the analyses. Most of them used data from registries (44%), while claims data 
were analyzed in 18% of cases and other data sources were represented in 38%. The 
majority (74%) used a prospective study design. Two thirds of the studies analyzed 
data on a brand specific level whereas the remainder mainly distinguished between 
different types of medical devices. Registry data was mostly used to address brand 
specific research questions (88%) while all claims data based studies investigated 
research questions on a non-brand specific level. Common research questions were 
cost comparisons, survival analyses, and burden of disease. cOnclusiOns: Various 
research questions can be answered by referring to RWE. Given the wide spectrum 
of medical devices, RWE is used only to a limited extent in the German setting, but 
is expected to become more important with changing regulation. However, careful 
considerations have to be made whether existing data sources can be utilized or 
new data needs to be generated to address specific research questions.
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improvement since 2007. MethOds: To determine the impact of HER2 testing quality 
improvement over years, we used a standardized 5-step methodology: 1) thesis state-
ment of the purpose of the project and the criteria to measure the value of an offer, 2) 
decision tree, 3) patient flow, 4) cost evaluation, 5) communication to stakeholders. For 
HER2 testing, considering costs and life saved as outcomes, we built a decision tree in 
order to describe the patient flow of patients diagnosed with breast cancer according 
to HER2 testing and treatment patterns. Two simulations were conducted for year 2007 
and 2014 according to HER2 testing improvement. Testing costs, medical staff and 
supply costs were considered. Results: Yearly, more than 48,700 malignant breast 
cancers (in situ not included) are diagnosed in France. In 2007 HER2 testing errors 
varied between 10% to 17% for false positive and between 4% to 8% for false negative 
respectively. These rates declined in 2014 to 7%-10% for false positive and 2%-4% for 
false negative respectively. This improvement of HER2 testing quality resulted in more 
patients receiving Herceptin at adjuvant stage. Consequently, over the 7 last years this 
led to annual increase of around 160-330 lives saved and a global increase of € 10M for 
drug spending. cOnclusiOns: As targeted therapies’ offer increases more and more 
in cancer treatment, besides treatment efficacy, it appears crucial to continue opti-
mizing patients profiling with performant testings relying on national quality control 
insurance. Education, recommendations and good practices workflow are mandatory
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Objectives: The Portuguese National Health System (NHS) identified the need to 
easily access information that allowed identification of all medical devices (MDs) 
with their respective manufacturers, distributors, characteristics, and purposes. 
The objective of the creation of an information system is to collect, store and ana-
lyze data of each MD and to provide NHS resources management, health technol-
ogy assessment (HTA), as well as data about the Portuguese market. MethOds: 
METHODS A system consisting of a database that is a repository, and an application 
system that stores the information was built. For the registry of information all MDs 
should disclose their respective instructions of use, labels and price. The concept of 
unique medical device and a process to assign a code to each device was designed, 
and tested by collecting data from NHS acquisitions. The prescription of medical 
devices is made by code (unique device identifier), with all information online. 
A model for communication between the health regulatory agency and market 
operators was also devised, as well as rules and codes of procedure. Results: The 
creation of this system in 2011 allowed for the coding of 44% of all registered MDs 
(n= 1000000) up to June 2015. This has allowed for the elimination or withdrawal 
of 21% (n= 215000) of references, thus keeping the registries up to date. The coding 
(unique device identifier), permitted the comparison of devices and the manage-
ment of total expenditure in MDs by hospitals of the NHS. cOnclusiOns: The 
system provides solid information about available MDs in the market, their respec-
tive manufacturer, distributor and pricing to which they are sold to the NHS. The 
system is a support for decision makers, payers, and HTA processes. It facilitates 
the management and traceability of medical devices in hospitals and has impact 
on reimbursement, access and pricing varies by market
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Objectives: There have been recent concerns about the association of ulcer-healing 
medications, including proton pump inhibitors (PPIs) with ischemic heart disease 
(IHD), including heart attacks. This issue has brought about media attention and 
could have implications on patient care in real-world settings. This pharmacovigi-
lance analysis aims to detect signals of IHD in patients treated with PPIs. MethOds: 
Adverse event reports submitted to the FDA Adverse Event Reporting System were 
used (cumulative to June 2014), and Multi-item Gamma Poisson Shrinker dispro-
portionality analysis algorithm was applied to calculate Empirical Bayes Geometric 
Mean (EBGM) and corresponding 95%CI (EB05-EB95) as association metrics. PPIs 
were defined by generic names, and IHD events were defined as structured MedDRA 
queries of Preferred Terms denoting to IHD. Safety signals were defined as drug-
event associations with EB05≥ 2.0. Signal detection of myocardial infarction (MI) 
was conducted as sensitivity analysis. Results: There were 1,731 cases of IHD 
reported for PPIs; of those, 74% (n= 1,279) were for MI. 52% of IHD reports were 
females (mean age= 63 years); 75% were from the US; 93% were reported by PPIs 
manufacturers within 15 days of IHD occurrence. 96% of reported IHD events were 
serious, corresponding to 13% fatalities; 7% life-threatening events; 50% required 
hospitalization; 6% disabilities; and 2% required medical intervention. Healthcare 
professionals and consumers contributed to 13% and 4% of reported IHD events, 
respectively. No disproportional reporting of IHD (EBGM= 0.74; EB05-EB95= 0.72-0.77) 
nor MI (EBGM= 0.69; EB05-EB95= 0.66-0.72) was found for PPIs. 57% of IHD cases 
had previous and concurrent treatment with cardiovascular medications (mean= 3 
medications per report). cOnclusiOns: Ulcer-healing treatment with PPIs is not 
associated with IHD, and protopathic bias could have contributed to the observed 
casual association in published studies, where PPIs could have been prescribed 
to treat gastric prodromal symptoms of MI. Pharmacoepidemiologic studies are 
required to further evaluate the impact of this bias.
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Objectives: The purpose of this study was to evaluate whether F-18 fluoromisoni-
dazole PET or PET/CT (FMISO) was safe and effective for malignant tumor patients 
and to determine a possibility of the introduction in Korea reimbursement regula-
tion. MethOds: A systematic literature review was used to evaluate the safety and 
effectiveness for FMISO. The 27 articles were selected and two reviewers evaluated 
independently the quality of these selected articles using the Scottish Intercollegiate 
Guidelines Network (SIGN) tool. Results: The correlation between tumor hypoxic 
imaging via FMISO and tumor imaging using existing imaging tests for diagnosing 
tumors in 14 articles was almost weak. By evaluating the hypoxic tumor lesions 
via FMISO, it was able to plan an intense radiotherapy that irradiate high dose in 
hypoxic area and to determine the therapeutic response and prognosis in 15 arti-
cles. cOnclusiOns: The FMISO supplement the information of the heterogene-
ous tumor microenvironment as an add-on test and is a safe and effective test to 
determine the treatment direction through dose planning, prognosis, checking of 
therapeutic response for malignant cancer patients. Based on this evidence, FMISO 
will be introduced to the market within reimbursement regulation.
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Objectives: The purpose of this study was to explore the effectiveness of thermodi-
lution technique method for vascular access flow measurement for the patients 
with hemodialysis were assessed. MethOds: A systematic review was conducted to 
identify relevant articles published until May 4, 2015. Ovid-MEDLINE, Ovid-EMBASE, 
The Cochrane Library and the international databases of health technology agen-
cies were searched using the term ‘thermodilution technique method’. The SIGN 
(Scottish Intercollegiate Guidelines Network) methodology checklists were used for 
critical appraisal. Two review authors independently applied the extracted data and 
assessed the study quality. After data extraction, descriptive analysis was carried 
out. Results: A total of 12 literatures were included in the final assessment by 
applying our inclusion criteria. As the result of systematic reivew, the correlation of 
thermodilution techinique metohd and saline dilution method obtained excellent 
correlation. Statistically significant differences were obtained in patients age (> 65 
years old) and peripheral vascular disease were associated with a significantly lower 
flow access. Reproducibility of thermodilution technique method and saline dilution 
method, expressed as relative differences, was significantly different from saline 
method. cOnclusiOns: Based on the current findings, we concluded that ther-
modilution technique method is effectiveness technology when used on patients 
with hemodialysis.
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Objectives: This study analysed the National Institute of Health and Care 
Excellence’s (NICE) Medical Technology Evaluation Programme (MTEP) to identify the 
drivers of decisions for medical devices. MethOds: All published MTEP appraisals 
were reviewed to capture data on the quality of submissions and outcomes, using a 
pre-designed data-extraction form. Results were analysed descriptively. Results: 
24 MTEP decisions are publically available. It was unclear if all submissions included 
a systematic literature review (SLR) as this was not routinely referenced. The clinical 
evidence submitted varied from unpublished observational data, to twenty-eight 
studies identified through a SLR, with a typical submission including three to twelve 
studies. Similarly, the complexity of economic evidence submitted varied; 87.5% con-
ducted cost-analyses or decision-trees, while 12.5% conducted Markov models. 75% 
of appraisals were positive, with NICE concluding that the technology was equally or 
more effective, and cost-saving or neutral compared to current care. In 66% of positive 
decisions, NICE noted the lack of robust clinical evidence. NICE accepted the results of 
observational studies and case-studies, particularly when randomised clinical trials 
were uncommon in a therapeutic area. In 28% of positive decisions, NICE disputed 
the model assumptions and revised the results but accepted the conclusions if cost-
savings were still demonstrated. In contrast, the rationale for all negative decisions 
was a lack of clinical evidence. In more than half of negative appraisals, NICE referred 
to the quality of the submission, noting that the SLR included studies out of scope 
or missed relevant studies or the submission relied heavily on poor quality studies. 
In all negative decisions, NICE encouraged further research. cOnclusiOns: A NICE 
MTEP submission is likely to result in a positive decision, if evidence collection is 
well-conducted, and the device demonstrates equivocal or better effectiveness and 
cost savings compared to standard care, even if limited clinical trials are available.
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Objectives: For HER2+ breast cancer patients, initiating the adapted treatment at 
an early stage increases the chance of survival. Between 2007 and 2014, quality of 
HER2 testing improved significantly, leading to lower rates of error on HER2 status. 
We developped a model to evaluate the public health impact of HER2 testing quality 
